Renal Cell Carcinoma | Topics

Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity, Maintains Safety in Metastatic RCC
July 28, 2021

The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.

Oncology Peer Review On-The-Go: Considering Second-Line Treatment Amidst Evolving Frontline Landscape for Clear Cell RCC
July 20, 2021

Robert A. Figlin, MD, spoke with CancerNetwork® about emerging second-line therapies as the paradigm of first-line treatment evolves for patients with metastatic clear cell renal cell carcinoma.

Robert A. Figlin, MD, on Adverse Effects of Cabozantinib in RCC
July 08, 2021

Robert A. Figlin, MD, highlights toxicities that patients with renal cell carcinoma experience while on cabozantinib.